Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Down 1.7 %

Shares of NERV opened at $1.76 on Friday. The business has a fifty day moving average of $1.63 and a 200 day moving average of $2.04. The company has a market cap of $12.31 million, a PE ratio of -4.00 and a beta of -0.09. Minerva Neurosciences has a 52-week low of $1.15 and a 52-week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.49. As a group, research analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Minerva Neurosciences

Several institutional investors and hedge funds have recently made changes to their positions in NERV. Citadel Advisors LLC grew its holdings in shares of Minerva Neurosciences by 49.5% in the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 8,525 shares during the last quarter. Northern Trust Corp lifted its holdings in Minerva Neurosciences by 60.0% during the 4th quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 13,829 shares in the last quarter. Finally, Apella Capital LLC purchased a new stake in Minerva Neurosciences in the 1st quarter valued at about $35,000. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.